Why the study?
Does correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes?
Does correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes?
Highlights the critical gap in trial evidence for lipid-lowering therapies specifically targeting coronary heart disease risk reduction in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
No trial evidence guides dyslipoproteinaemia correction for CHD risk in NIDDM; leaves open need for dedicated RCTs.
Pyörälà et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: